

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
February 9, 2023

**DRAFT MEETING ROSTER**

---

---

**ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)**

**Rhea Bhatt**

Division of Advisory Committee and Consultant Management  
Office of Executive Programs, CDER, FDA

**ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)**

**Mark Conaway, PhD**

Professor and Director of Translational Research  
Division of Translational Research and Applied  
Statistics  
Department of Public Health Sciences  
University of Virginia  
Charlottesville, Virginia

**Jorge A. Garcia, MD, FACP**

*(Chairperson)*  
Chief, Division of Solid Tumor Oncology  
George and Edith Richman Distinguished Scientist  
Chair  
Professor of Medicine and Urology  
GU Medical Oncology Program  
University Hospitals Seidman Cancer Center  
Case Comprehensive Cancer Center  
Case Western Reserve University  
Cleveland, Ohio

**Pamela L. Kunz, MD**

Associate Professor of Medicine (Oncology)  
Division Chief, GI Oncology  
Vice Chief  
Diversity Equity and Inclusion, Medical Oncology  
Yale School of Medicine and Yale Cancer Center  
New Haven, Connecticut

**Christopher H. Lieu, MD**

Associate Professor of Medicine  
Associate Director for Clinical Research  
co-Director, Gastrointestinal Medical Oncology  
University of Colorado Cancer Center  
Aurora, Colorado

**Ravi A. Madan, MD**

Senior Clinician, Genitourinary Malignancies Branch  
Head, Prostate Cancer Clinical Research Section  
Program Director, Physician-Scientist Early  
Investigator Program  
Center for Cancer Research  
National Cancer Institute  
National Institutes of Health  
Bethesda, Maryland

**David E. Mitchell**

*(Consumer Representative)*  
Founder, Patients for Affordable Drugs  
Bethesda, Maryland

**Jorge J. Nieva, MD**

Associate Professor of Clinical Medicine  
Section Head, Solid Tumors  
University of Southern California (USC) Norris  
Comprehensive Cancer Center  
Keck School of Medicine of USC  
Los Angeles, California

**Neil Vasan, MD, PhD**

Assistant Professor of Medicine  
Division of Hematology & Oncology  
Department of Medicine  
Herbert Irving Comprehensive Cancer Center  
Columbia University Medical Center  
New York, New York

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
February 9, 2023

**DRAFT MEETING ROSTER (cont.)**

---

---

**ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)**

**Albert L. Kraus, PhD**

*(Acting Industry Representative)*  
Global Regulatory Portfolio Lead – Oncology  
Pfizer, Inc.  
Guilford, Connecticut

**TEMPORARY MEMBERS (Voting)**

**George J. Chang, MD, MS**

Professor and Chair ad interim  
Department of Colon and Rectal Surgery  
Sue and Radcliffe Killam Chair  
Associate Vice President, Regional Surgery  
Strategy  
The University of Texas, MD Anderson Cancer  
Center  
Houston, Texas

**Kristen K. Ciombor, MD, MSCI**

Associate Professor of Medicine  
Department of Internal Medicine  
Division of Hematology/Oncology  
Vanderbilt University Medical Center  
Vanderbilt-Ingram Cancer Center  
Nashville, Tennessee

**Evangelia Katsoulakis, MD**

Veterans Affairs (VA) Hospital  
Department of Radiation Oncology and Clinical  
Informatics  
Associate Professor Radiation Oncology  
University of South Florida  
Tampa, Florida

**Paul V. Majkowski, Esq.**

*(Patient Representative)*  
Albertson, New York

**John H. Park, MD**

Staff Physician  
Department of Radiation Oncology  
Kansas City VA Medical Center  
Clinical Assistant Professor  
University of Missouri Kansas City  
Kansas City, Missouri

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Oncologic Drugs Advisory Committee (ODAC) Meeting***  
February 9, 2023

**DRAFT MEETING ROSTER (cont.)**

---

---

**FDA PARTICIPANTS (Non-Voting)**

**Richard Pazdur, MD**

Director, Oncology Center of Excellence (OCE)  
Director (Acting)  
Office of Oncologic Diseases (OOD)  
Office of New Drugs (OND), CDER, FDA

**Paul Kluetz, MD**

Deputy Center Director, OCE  
Supervisory Associate Director (Acting)  
OOD, OND, CDER, FDA

**Steven Lemery, MD, MHS**

Director  
Division of Oncology Products 3 (DO3)  
OOD, OND, CDER, FDA

**Lola Fashoyin-Aje, MD, MPH**

Deputy Director  
DO3, OOD, OND, CDER, FDA

**Sandra Casak, MD**

Clinical Team Leader  
Gastrointestinal Cancers Team  
DO3, OOD, OND, CDER, FDA